Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06024915
Other study ID # TQ05105-I-04
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date September 2023
Est. completion date December 2023

Study information

Verified date May 2023
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Xin Wang, MD, PhD
Phone 86-0531-68778331
Email xinw007@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of metabolic enzyme inhibitors/inducers on in vivo metabolic and elimination of TQ05105 tablets, and the safety of metabolic enzyme inhibitors/inducers combined with TQ05105 tablets.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date December 2023
Est. primary completion date October 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - At the time of signing the informed consent, males or females between 18 and 45 years of age; - Female weight = 45 kg, male weight = 50 kg, with a body mass index (BMI) between 19 and 26 kg/m2. - Subjects in good health, as determined by a medical history, vital signs, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations; - Subjects can comply with the study procedures, voluntarily participate in the study, and sign the informed consent in person. Exclusion Criteria: - Subjects: preexisting or existing circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry and metabolic disorders or abnormalities, or related chronic or acute diseases, the investigator assesses that it is not appropriate to participate in the trial; - Subjects with Systemic/local acute infection before taking the study drug; - Subjects who have a history of specific allergies, or allergic conditions (such as allergies to two or more drugs, environments, or foods), or are known to be allergic to components or analogs of the study drug; - Subjects who have difficulty in swallowing or have any gastrointestinal disorder that affects drug absorption at the time of screening; - Subjects who cannot receive venous indwelling needle for blood sample collection; - Subjects who drank regularly in the 6 months prior to first dosing, such as those who drank more than 14 units of alcohol per week or who had a positive alcohol breath test at the time of screening; - Subjects who had a history of major surgery, or had taken the study drug, or had participated in other drug clinical trials within 3 months prior to initial dosing; - Subjects who donated blood or lost significant amounts of blood within 3 months prior to initial dosing; - Subjects who had used drugs within 3 months prior to first dosing, or tested positive for drugs, or had a history of drug abuse within 5 years prior to screening; - Subjects who smoked more than 5 cigarettes per day in the 3 months prior to initial dosing or who could not stop using any tobacco products during the trial; - Subjects who consumed excessive amounts of tea, coffee, and/or caffeinated beverages daily in the 30 days prior to initial dosing; - Subjects who have used any drug that inhibits or induces liver metabolism of the drug in the 30 days prior to initial dosing; - Subjects who have taken any prescription, over-the-counter, herbal, or health product in the 14 days prior to initial dosing; - Subjects who have taken a special diet or other factors affecting drug absorption, distribution, metabolism, or excretion within 7 days prior to initial dosing; - Subjects who ingested chocolate, any caffeinated, or xanthine-rich food or drink 48 hours before first dosing; - Subjects who have special dietary requirements and cannot follow a uniform diet; - Female subjects of child-bearing potential; - Subjects judged by the investigator to be unsuitable to participate.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TQ05105 tablets
TQ05105 is a Janus kinase 2 (JAK2) inhibitor.
Itraconazole capsule
Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).
Rifampicin Capsule
Rifampicin is a strong inducer of CYP3A.

Locations

Country Name City State
China Shandong Provincial Hospital Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum plasma concentration (Cmax) Maximum plasma drug concentration after administration. Up to 10 days.
Primary Time to reach Cmax (Tmax) Time to reach the maximum plasma concentration after administration. Up to 10 days.
Primary Elimination half-life (t1/2) The elimination half-life (t1/2) after oral dose of TQ05105 tablets and Itraconazole capsule. Up to 6 days.
Secondary Occurrence of adverse events (AE) Including all adverse events (AE) and serious adverse events (SAE). Up to 30 days.
See also
  Status Clinical Trial Phase
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Not yet recruiting NCT06345495 - High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Completed NCT02784496 - Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis Phase 2
Completed NCT00069680 - Genetic Analysis of Gray Platelet Syndrome
Active, not recruiting NCT04097821 - Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Phase 1/Phase 2
Active, not recruiting NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting NCT06397313 - RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT02910258 - Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00666549 - Research Tissue Bank
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Terminated NCT00522990 - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Phase 1/Phase 2
Completed NCT00606437 - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants Phase 1
Active, not recruiting NCT03952039 - An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Phase 3
Not yet recruiting NCT04709458 - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis Phase 1
Recruiting NCT04988815 - Ropeginterferon Alfa 2b for Early Myelofibrosis Phase 2